Maravai LifeSciencesの空売り状況は、投資家がMaravai LifeSciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Maravai LifeSciences (NASDAQ:MRVI) 株価情報, 空売り情報

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Needham analyst Quinn Bolton maintains Synaptics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYNA#NASDAQ">SYNA</a>) with a Buy and lowers the price target from $95 to $90.

News

Price Target

Analyst Ratings

SYNA

Needham Maintains Buy on Synaptics, Lowers Price Target to $90

Barclays analyst Kannan Venkateshwar maintains Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a Equal-Weight and raises the price target from $8 to $10.

Barclays Maintains Equal-Weight on Warner Bros. Discovery, Raises Price Target to $10

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

Reiteration

MLTX

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Crypto analysts are seeing signals that Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) may soon rally against Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), potentially <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40255976/is-ethereum-going-to-keep-underperforming-bitcoin-heres-what-technical-analysis-says">reversing recent underperformance</a>.
What Happened: According to Lookonchain, a major Ethereum whale with holdings of 398,891 ETH ($1.14 billion) recently sold 29,897 ETH at $2,839 for a profit of $84.7 million (810x return), <a href="https://x.com/lookonchain/status/1854735745099219430">signaling</a> confidence among some high-stake investors in ETH&#8217;s future trajectory. He continues to hold 368,992 ETH ($1.07 billion).
Ethereum has rallied 17% over the past seven days, prompting bullish forecasts from traders and analysts:
<ul>
<li>Crypto trader &#8220;Astronomer&#8221; swapped half of his BTC for ETH, calling it "the meme trade of the year." He points out that while BTC is up 30%, ETH has risen only 10% but predicts Ethereum's rally will follow, targeting a 70% increase in ETH/BTC. He <a href="https://x.com/astronomer_zero/status/1854418883140296828">added</a>, "Now that the majority of the BTC dominated move of this breakout leg is taking place, it just comes down to catch the ETH dominated move next."</li>
<li>Analyst Benjamin Cowen <a href="https://x.com/intocryptoverse/status/1854259773144981768">offered</a> a measured take, noting, "If ETH can break its bull market support on weekly closes, my position might change." He continues to hedge cautiously with the ETH/BTC ratio at 0.035.</li>
<li>Adding to the discussion, Michaël van de Poppe <a href="https://x.com/CryptoMichNL/status/1854441159583785087">observes</a>, "The markets are rotating, as ETH has a massive bounce upwards." He suggests that if ETH can establish a higher low, it could continue its upward momentum.</li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a>
Why It Matters: This mix of bullish and cautious viewpoints reflects the complex nature of crypto market behaviour, with some analysts seeing Ethereum poised for significant gains. Investors are advised to consider diverse perspectives as the market remains highly volatile.
IntoTheBlock data shows large transaction volume for Ethereum decreased by 0.7% with active addresses up 7.4% and high-value transactions falling from 7,274 to 7,648. Net exchange flows, however, are up by 2,155.7%.
Despite an underperformance of ETH against BTC over the past month, 74% of holders are still making a profit.
What&#8217;s Next: The influence of <a href="https://www.benzinga.com/money/is-ethereum-a-good-investment" target="_blank" rel="noreferrer noopener">Ethereum as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41796743/ethereum-whales-wake-up-from-slumber-to-cash-out-90m-amid-rally-but-indicators-show-sentim">Ethereum Whales Wake Up From Slumber To Cash Out $90M Amid Rally, But Indicators Show Sentiment Can Flip</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Ethereum Up 17% On The Week: What Is Going On?

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) with a Buy and lowers the price target from $45 to $41.

RNAC

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $41

Ciena's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) short percent of float has risen 3.56% since its last report. The company recently reported that it has 6.11 million shares sold short, which is 5.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ciena Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093400_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ciena has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ciena's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ciena's peer group average for short interest as a percentage of float is 7.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CIEN

Peering Into Ciena's Recent Short Interest

Kraft Heinz's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NYSE">KHC</a>) short percent of float has fallen 3.77% since its last report. The company recently reported that it has 33.76 million shares sold short, which is 3.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kraft Heinz Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093395_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kraft Heinz has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Kraft Heinz's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kraft Heinz's peer group average for short interest as a percentage of float is 4.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Kraft Heinz's Recent Short Interest

Cheniere Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) short percent of float has risen 7.09% since its last report. The company recently reported that it has 3.39 million shares sold short, which is 1.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cheniere Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731093389_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cheniere Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cheniere Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cheniere Energy's peer group average for short interest as a percentage of float is 3.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Cheniere Energy's Recent Short Interest

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $240 to $260.

VEEV

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $260

HC Wainwright &amp; Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKUR#NASDAQ">OKUR</a>) with a Buy and maintains $40 price target.

OKUR

HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $40 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and lowers the price target from $6 to $5.

RLYB

HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $5

<a href="https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales">https://www.bloomberg.com/news/articles/2024-11-08/toyota-executive-lashes-out-at-us-regulations-promoting-ev-sales</a>
&nbsp;
Toyota Motor Corp.'s North American chief operating officer criticized the US's policies promoting speedy adoption of electric vehicles, calling them "de facto mandates" out of sync with consumer demand.

Management

Global

'Toyota Executive Lashes Out At U.S. Regulations Promoting EV Sales' - Bloomberg News

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and raises the price target from $27 to $39.

CARG

Needham Maintains Buy on CarGurus, Raises Price Target to $39

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $50 to $57.

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Barclays analyst Jared Shaw maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and raises the price target from $56 to $64.

Barclays Maintains Overweight on Synovus Finl, Raises Price Target to $64

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/MSI/earnings">FY24 adjusted EPS guidance above estimates on Thursday.</a>
Motorola Solutions reported quarterly earnings of $3.74 per share which beat the analyst consensus estimate of $3.38 per share. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.76 billion.
&#8220;Our third-quarter results were exceptional, with record Q3 revenue, earnings and cash flow,&#8221; said Greg Brown, chairman and CEO, Motorola Solutions. &#8220;We achieved strong growth across the board, and I&#8217;m pleased with the momentum of our business. As a result, we&#8217;re again raising our revenue and earnings expectations for the full year.&#8221;
Motorola Solutions shares gained 6.8% to trade at $501.80 on Friday.
These analysts made changes to their price targets on Motorola Solutions following earnings announcement.
<ul>
<li>Raymond James analyst Adam Tindle maintained Motorola with an Outperform and raised the price target from $425 to $515.</li>
<li>Barclays analyst Tim Long maintained the stock with an Overweight and raised the price target from $467 to $529.</li>
</ul>
Considering buying MSI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png" alt="" class="wp-image-638367" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Markets

These Analysts Raise Their Forecasts On Motorola Solutions Following Q3 Earnings

HC Wainwright &amp; Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) with a Buy and maintains $13 price target.

TNGX

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Underweight and raises the price target from $245 to $255.

Barclays Maintains Underweight on Rockwell Automation, Raises Price Target to $255

WIIM

Canopy Growth shares are trading lower. The company reported Q2 financial results.

PGIM Jennison Health Sciences Fund Q2 2024 Commentary

In a report released on September 6, Brandon Couillard from Wells Fargo maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research R...

Maravai Lifesciences Holdings (MRVI) Gets a Buy from Wells Fargo

Codexis licenses Genomics Life Science enzyme portfolio to Alphazyme LLC

RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on October 23 and set a price ...

RBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)

Reports Q3 revenue $65.2M, consensus $67.55M. "We achieved significant milestones this quarter, launching innovative new products across the portfo...

Maravai Lifesciences reports Q3 adjusted EPS (2c), consensus (1c)

Consensus $275.55M. The company said, "Maravai's financial guidance for the full year 2024 is based on expectations for its existing business and d...

Maravai Lifesciences lowers FY24 revenue view to $255M-$265M from $265M-$285M

RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) today and set a price target o...

RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)

RBC Capital lowered the firm's price target on Maravai Lifesciences (MRVI) to $13 from $17 and keeps an Outperform rating on the shares after its w...

Maravai Lifesciences price target lowered to $13 from $17 at RBC Capital

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Eyes are on Nvidia (NVDA) during its f...

Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz

Maravai LifeSciences stock plunges 39% amid lowered revenue forecast

ABBV

ABNB

AMGN

AMZN

APLS

ARGX

BBWI

BLMN

CABA

CDXS

DKNG

DOCS

EXPE

INDI

INOD

ISRG

MRNS

MRVI

NVDA

PAAA

PFRL

PHYL

PINS

PJFG

PJIO

PMIO

PRCH

PSDM

PTRB

PULS

RIVN

RVNC

SHOO

STLA

TOST

UPST

VRTX

Press Releases

Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024

Maravai LifeSciences Appoints Trey Martin to Board of Directors

Maravai LifeSciences Reports Second Quarter 2024 Financial Results

Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule

Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

Maravai LifeSciences Reports Third Quarter 2024 Financial Results

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

Agilent Technologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

RBC Capital

Baird

Goldman Sachs

Wells Fargo

Morgan Stanley

Maravai LifeSciences shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 sales guidance. Additionally, William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

Comments

Maravai LifeSciences

空売り

Maravai LifeSciences (NASDAQ:MRVI) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル